Condition
Metastases to Bone
Total Trials
5
Recruiting
2
Active
2
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 2 (1)
Trial Status
Recruiting2
Completed1
Withdrawn1
Not Yet Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07043608Phase 2Not Yet Recruiting
Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases
NCT07538024Not ApplicableRecruitingPrimary
Pilot Randomized Study for Treatment Volume De-Escalation for Spinal Metastases With Stereotactic Body Radiation Therapy
NCT04170634RecruitingPrimary
Tumoral Bone Strength Assessment by Numerical Simulation Using Quantitative CT : the MEKANOS Study
NCT06244498CompletedPrimary
Tranexamic Acid After Pathological Fracture Treated With Modular Arthroplasty
NCT03134404WithdrawnPrimary
Project to Assess Feasibility of a Rapid Access Metastatic Bone Disease Program
Showing all 5 trials